A method of screening/prognosis/diagnosis for colorectal cancer (CRC) wherein methionine aminopeptidase 2 (MetAP2) levels are detected in a non-tumor sample such as peripheral blood, peripheral blood mononuclear cells (PBMC) or lymphocytes. Based on the MetAP2 levels, the individual may be selected for further testing.

The present invention relates to detecting serum anti-FadA antibodies in test samples from a patient. Additionally, aspects of the present invention provide the basis for detection of serum anti-FadA antibody levels from test samples and correlation with various conditions of clinical relevance.

A method, a composition and a kit for screening an ALK or ROS-1 kinase inhibitor are disclosed in the present specification. In an aspect, by the method, composition and kit for screening an ALK or ROS-1 kinase inhibitor according to the present disclosure, it is possible to conduct simultaneous quantitative and qualitative analysis and faster screening of a larger number of candidate substances as compared with conventional molecular biological experimental methods and to grasp the overall level of change in a plurality of different metabolites in a cell line by candidate substances of ALK or ROS-1 kinase inhibitor and thus the screening efficiency for drugs which exert an ALK or ROS-1 kinase inhibitory effect is excellent. Consequently, the present disclosure has an advantage of being able to be used in various ways in the development of new drugs which exert an ALK or ROS-1 kinase inhibitory effect.

The present invention relates to compositions and methods for diagnosing and treating colorectal cancer.

Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided. The methods may include obtaining a sample from the subject, determining an expression level of at least one biomarker selected from the group consisting of VEGF-D and PlGF in a sample from the subject, comparing the expression level of the biomarker in the sample to a reference level of the biomarker, and predicting the responsiveness of the cancer to treatment with the cancer therapy including a VEGF targeting agent. Optionally, the methods may further include administering a VEGF target agent and/or an anticancer or chemotherapy agent to the subject. Additional methods of prognosing and treating a cancer in a subject are also provided.

The present invention discloses methods of identifying subject having an increased risk to develop an N-glycolylneu-raminic acid (Neu5Gc) related disease, methods for assessment risk factors related to a consumption of Neu5Gc from food and methods of predicting the likelihood of developing of Neu5Gc related disease or disorder.

Methods and compositions are provided herein for treating colorectal cancer in a subject, using one or more bacterial strains such as Bacteroides eggerthii 1 2 48FAA, Bacteroides eggerthii CCUG 9559, Bacteroides goldsteinii ATCC BAA 1180, Bacteroides pectinophilus N3, Bacteroides plebeius M12, Bacteroides vulgatus 8482, Barnesiella intestinihominis DSM 21032, Bifidobacterium stercoris EG1, Clostridium sp. 40, Clostridium spiroforme CCM 6168, Eubacterium eligens DSM 3376, Eubacterium hallii DSM 3353, Megamonas funiformis DSM 19343, Megasphaera elsdenii LC1, Parabacteroides johnsonii M-165, Butyricimonas virosa MT12, Clostridium citroniae DSM 19261, Lactobacillus ruminis RF3, Methanosphaera stadtmanae MCB-3, Ruminococcus sp. 18P13, Slackia piriformis DSM 22477, or Streptococcus hongkongensis HKU30.

The present invention relates to an apparatus for diagnosing solid cancers comprising lung cancer, pancreatic cancer, bile duct cancer, colorectal cancer, breast cancer, gastric cancer, brain tumors, kidney cancer, liver cancer, and cervical cancer. More specifically, the apparatus comprises: a concentration measurement unit for measuring the concentration of each of acyl-carnitine (AC), nudifloramide (2PY), and lysophosphatidylcholine (LPC) from a biological sample; a pre-processing unit for pre-processing the measured concentrations; and a diagnosis unit for determining the diagnosis information of cancer through linear discriminant analysis using the pre-processed concentrations.

The present invention relates to a method of using Focal Adhesion Kinase (FAX) as a predictive marker to identify patients with early-stage colorectal cancer (CRC) at risk for recurrence. In particular, the present invention is a prognostic assay using FAK protein expression to predict those CRC patients with Stage I disease who may recur. The present invention will allow for quantitative measurement of the expression of FAK in tumor tissue of patients with early-stage CRC. As patients with stage I CRC are typically only treated with surgical resection, the present invention will uniquely facilitate the identification of those early-stage CRC patients who are at risk of recurrence and who may benefit from adjuvant therapy after resection of the primary cancer. This invention is not limited to patients with CRC and may be utilized for any condition that is caused by or causes FAK overexpression or dysfunction.

From gene expression analysis with a long-term recurrence-free group and a recurrence metastasis group of stomach cancer, CHRNB2 and NPTXR were identified as drug discovery targets. Tumor growth was successfully inhibited by an antibody medicine or a nucleic acid medicine targeting CHRNB2 or NPTXR. Furthermore, a polyclonal antibody and a monoclonal antibody linking to CHRNB2 or NPTXR are provided. Since these receptor molecules are novel molecular targets, treatment of cases which the existing therapeutic drugs have no effect on is made possible.